Neffy is a drug owned by Ars Pharmaceuticals Operations Inc. It is protected by 7 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 06, 2039. Details of Neffy's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11191838 | Intranasal epinephrine formulations and methods for the treatment of disease |
Feb, 2039
(14 years from now) | Active |
| US11744895 | Intranasal epinephrine formulations and methods for the treatment of disease |
Feb, 2039
(14 years from now) | Active |
| US11717571 | Intranasal epinephrine formulations and methods for the treatment of disease |
Feb, 2039
(14 years from now) | Active |
| US11918655 | Intranasal epinephrine formulations and methods for the treatment of disease |
Feb, 2039
(14 years from now) | Active |
| US10682414 | Intranasal epinephrine formulations and methods for the treatment of disease |
Feb, 2039
(14 years from now) | Active |
| US10576156 | Compositions for drug administration |
Feb, 2038
(13 years from now) | Active |
| US11173209 | Compositions for drug administration |
Feb, 2038
(13 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Neffy is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Neffy's family patents as well as insights into ongoing legal events on those patents.
Neffy's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Neffy's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 06, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Neffy Generic API suppliers:
Epinephrine is the generic name for the brand Neffy. 4 different companies have already filed for the generic of Neffy, with Am Regent having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Neffy's generic
Alternative Brands for Neffy
There are several other brand drugs using the same active ingredient (Epinephrine) as Neffy. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Adamis Pharms Corp |
| |||
| Armstrong Pharms |
| |||
| Baxter Hlthcare Corp |
| |||
| Bpi Labs |
| |||
| Endo Operations |
| |||
| Impax |
| |||
| Inforlife |
| |||
| Kaleo Inc |
| |||
| Long Grove Pharms |
| |||
| Mylan Speciality Lp |
| |||
| Vyteris |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Epinephrine, Neffy's active ingredient. Check the complete list of approved generic manufacturers for Neffy
About Neffy
Neffy is a drug owned by Ars Pharmaceuticals Operations Inc. Neffy uses Epinephrine as an active ingredient. Neffy was launched by Ars Pharms Operation in 2024.
Approval Date:
Neffy was approved by FDA for market use on 09 August, 2024.
Active Ingredient:
Neffy uses Epinephrine as the active ingredient. Check out other Drugs and Companies using Epinephrine ingredient
Dosage:
Neffy is available in spray form for nasal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2MG/SPRAY | SPRAY | Prescription | NASAL |